In randomized clinical trials, the androgen receptor inhibitor enzalutamide has demonstrated efficacy and safety in metastatic castration-resistant prostate cancer (mCRPC). This study captured efficacy, safety, and patient-reported outcomes (PROs) of enzalutamide in mCRPC patients in a real-world European setting.